Raymond James added Cogent Biosciences (COGT) to the firm’s Analyst Current Favorites list. The list contains the current favorite stock ideas from the firm’s equity analysts. An analyst may only have one “buy” idea on the list at any given time.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COGT:
- Cogent Biosciences Signs Lease for New Headquarters
- Optimistic Buy Rating for Cogent Biosciences Driven by Bezuclastinib’s Potential and Expected 68.2% Share Price Return
- Promising Market Potential for Cogent Biosciences’ Bezuclastinib in Systemic Mastocytosis Treatment
- Cogent Biosciences initiated with a Strong Buy at Raymond James
- Cogent Biosciences price target raised to $20 from $17 at Guggenheim